Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.
The driving force behind oncoproteomics is to identify biomarker signatures associated with a particular malignancy. Here, we have for the first time used large-scale recombinant scFv antibody microarrays in an attempt to classify metastatic breast cancer versus healthy controls, based on differential protein expression profiling of whole serum samples. Using this multiplexed and miniaturised assay set-up providing pM range sensitivities, breast cancer could be classified with a specificity and sensitivity of 85% based on 129 serum analytes. However, by adopting a condensed 11 analyte biomarker signature, composed of nine non-redundant serum proteins, we were able to distinguish cancer versus healthy serum proteomes with a 95% sensitivity and specificity, respectively. When a subgroup of patients, not receiving anti-inflammatory drugs, was analysed, a novel eight analyte biomarker signature with a further improved predictive power was indicated. In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients.
Carlsson
Anders
A
Department of Immunotechnology, Lund University, BMC D13, SE-221 84 Lund, Sweden.
Wingren
Christer
C
Ingvarsson
Johan
J
Ellmark
Peter
P
Baldertorp
Bo
B
Fernö
Mårten
M
Olsson
Håkan
H
Borrebaeck
Carl A K
CA
D000368:Aged; D000912:Antibodies, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods*; D011994:Recombinant Proteins / Q000378:metabolism; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D011994:Recombinant Proteins